Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Novavax rose nearly 1% after the open on Friday, continuing a positive streak with gains expected for the third ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.02 which represents a slight increase of $0.20 or 2.27% from the prior close of $8.82. The stock opened at $8.77 and touched a low of ...

Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely ...

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets on ...

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates ...

On Tuesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $8.77 which represents a decrease of $-0.30 or -3.31% from the prior close of $9.07. The stock opened at $9.1 and touched a low of ...

The results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-MTM) show it is well-tolerated and offers ...

Shares of Novavax Inc. NVAX slid 3.31% to $8.77 Tuesday, on what proved to be an all-around poor trading session for the ...